Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

ConditionAcute Myeloid Leukemia

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorUniversity of Freiburg

About this trial

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

Eligibility criteria

Qualifiers

Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements

Hematological relapse after allo-HCT

18 years or older

Disqualifiers

no signed informed consent

Trial design

Treatments tested in this trial

Not listed

Trial groups

20 Participants

are grouped into 1 trial group

Sponsors and collaborators

University of Freiburg

Lead sponsor

Source ClinicalTrials.gov